Logo image
Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers
Journal article   Open access

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Utaroh Motosugi, Peter Bannas, Diego Hernando, Mandi Salmani Rahimi, James H. Holmes and Scott B. Reeder
Magnetic resonance in medical sciences, Vol.15(1), pp.60-72
01/01/2016
DOI: 10.2463/mrms.2015-0005
PMID: 26104082
url
https://doi.org/10.2463/mrms.2015-0005View
Published (Version of record) Open Access

Abstract

Purpose: We performed a quantitative intraindividual comparison of the performance of 0.025- and 0.05-mmol/kg doses for gadoxetic acid-enhanced liver magnetic resonance (MR) imaging. Materials and Methods: Eleven healthy volunteers underwent liver MR imaging twice, once with a 0.025- and once with a 0.05-mmol/kg dose of gadoxetic acid. MR spectroscopy and 3-dimensional gradient-echo T-1-weighted images (3D-GRE) were obtained before and 3, 10, and 20 mm after injection of the contrast medium to measure T-1 and T-2 values and signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) performance. During the dynamic phase, highly time-resolved 3D-GRE was used to estimate the relative CNR (CNRrel) of the hepatic artery and portal vein (PV) to the liver. We used paired t-tests to compare the results of different doses. Results: During the hepatobiliary phase, we observed shorter T-1 values and higher SNRs of the liver (P < 0.001) and higher liver-to-PV and liver-to-muscle CNRs (P < 0.002) using 0.05 mmol/kg compared to 0.025 mmol/kg. Increasing the dose to 0.05 mmol/kg yielded a greater T-1-shortening effect at 10 mm delay even compared with 0.025 mmol/kg at 20 mm (P < 0.001). During the dynamic phase, the peak CNRrel for the hepatic artery and portal vein were higher using 0.05 mmol/kg (P = 0.007 to 0.035). Conclusion: Use of gadoxetic acid at a dose of 0.05 mmol/kg leads to significantly higher SNR and CNR performance than with 0.025 mmol/kg. Quantitatively, a 10-min delay may be feasible for hepatobiliary-phase imaging when using 0.05 mmol/kg of gadoxetic acid.
Life Sciences & Biomedicine Radiology, Nuclear Medicine & Medical Imaging Science & Technology

Details

Metrics

Logo image